HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yasufumi Shirasaki Selected Research

Calmodulin (Calcium-Dependent Activator Protein)

1/2011CaMKIIδB mediates aberrant NCX1 expression and the imbalance of NCX1/SERCA in transverse aortic constriction-induced failing heart.
2/2010Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) in left ventricular hypertrophied Mice.
4/2006Involvement of calmodulin in neuronal cell death.
9/2005Inhibition of nitric oxide production and protein tyrosine nitration contribute to neuroprotection by a novel calmodulin antagonist, DY-9760e, in the rat microsphere embolism.
6/2005Cytoprotective effect of 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) against ischemia/reperfusion-induced injury in rat heart involves inhibition of fodrin breakdown and protein tyrosine nitration.
4/2005DY-9760e, a calmodulin antagonist, reduces brain damage after permanent focal cerebral ischemia in cats.
11/2004Protective effect of DY-9760e, a calmodulin antagonist, against neuronal cell death.
9/2004Serum S-100b protein as a biomarker for the assessment of neuroprotectants.
5/2004DY-9760e, a novel calmodulin antagonist, reduces infarction after permanent focal cerebral ischemia in rats.
3/20033-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e), a novel calmodulin antagonist, reduces brain edema through the inhibition of enhanced blood-brain barrier permeability after transient focal ischemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yasufumi Shirasaki Research Topics

Disease

11Ischemia
09/2010 - 03/2003
8Brain Ischemia (Cerebral Ischemia)
07/2006 - 05/2004
5Brain Injuries (Brain Injury)
04/2006 - 05/2004
4Hypertrophy
02/2010 - 12/2007
4Infarction (Infarctions)
01/2006 - 05/2004
4Stroke (Strokes)
04/2005 - 03/2003
3Embolism (Embolus)
10/2006 - 09/2005
3Brain Edema (Cerebral Edema)
10/2006 - 03/2003
3Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
07/2006 - 03/2003
2Heart Failure
01/2011 - 02/2010
1Cerebral Hemorrhage
04/2014
1Thrombosis (Thrombus)
04/2014
1Hemolysis
05/2012
1Parkinson Disease (Parkinson's Disease)
09/2010
1Hypoxia (Hypoxemia)
09/2010
1Cardiomegaly (Heart Hypertrophy)
01/2009
1Brain Infarction
09/2005
1Intracranial Embolism
09/2005
1Coronary Occlusion
06/2005
1Cerebral Infarction
04/2005

Drug/Important Bio-Agent (IBA)

123- (2- (4- (3- chloro- 2- methylphenyl)1- piperazinyl)ethyl)5,6- dimethoxy- 1- (4- imidazolylmethyl)- 1H- indazol dihydrochloride 3.5 hydrateIBA
02/2010 - 03/2003
10Calmodulin (Calcium-Dependent Activator Protein)IBA
01/2011 - 03/2003
8IndazolesIBA
02/2010 - 03/2003
5Proteins (Proteins, Gene)FDA Link
01/2011 - 06/2005
3CalpainIBA
02/2010 - 05/2006
3Pharmaceutical PreparationsIBA
02/2010 - 03/2003
3Tyrosine (L-Tyrosine)FDA Link
01/2006 - 06/2005
3Neuroprotective AgentsIBA
09/2004 - 05/2004
2AntithrombinsIBA
04/2014 - 05/2012
2DystrophinIBA
02/2010 - 12/2007
23- (2- (4- (3- chloro- 2- methylphenyl)- 1- piperazinyl)ethyl)- 5,6- dimethoxyindazoleIBA
01/2009 - 12/2007
2Endothelin-1 (Endothelin 1)IBA
01/2009 - 12/2007
2Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
01/2009 - 12/2007
2CalcineurinIBA
12/2007 - 07/2006
2fodrinIBA
01/2006 - 06/2005
2Evans Blue (Blue, Evans)FDA Link
06/2005 - 03/2003
1Factor Xa InhibitorsIBA
04/2014
1melagatranIBA
04/2014
1edoxabanIBA
04/2014
1Heparin (Liquaemin)FDA LinkGeneric
04/2014
1Collagenases (Collagenase)FDA Link
04/2014
1ThrombinFDA Link
05/2012
1Adenosine Triphosphatases (ATPase)IBA
01/2011
1Amino Acid Transport System X-AG (Glutamate Transporter)IBA
09/2010
1benzyloxyaspartate (TBOA)IBA
09/2010
1Aspartic Acid (Aspartate)FDA Link
09/2010
1Bromocriptine (Parlodel)FDA LinkGeneric
09/2010
1Glutamic Acid (Glutamate)FDA Link
09/2010
1Dopamine (Intropin)FDA LinkGeneric
09/2010
1SpectrinIBA
02/2010
1Indicators and Reagents (Reagents)IBA
02/2010
1U 0126 (UO 126)IBA
01/2009
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2009
1Atrial Natriuretic Factor (ANF)IBA
01/2009
1Calcium-Calmodulin-Dependent Protein KinasesIBA
01/2009
1Brain Natriuretic Peptide (Natrecor)FDA Link
01/2009
1Angiotensin IIIBA
12/2007
1phospholambanIBA
12/2007
1Phenylephrine (Neo-Synephrine)FDA LinkGeneric
12/2007
1Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
10/2006
1calpastatinIBA
05/2006
1Caspase 3 (Caspase-3)IBA
05/2006
1ChloridesIBA
05/2006
1Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA
09/2005
1Nitric Oxide (Nitrogen Monoxide)FDA Link
09/2005
1triphenyltetrazoliumIBA
06/2005
1Dizocilpine Maleate (Dizocilpine)IBA
09/2004
1N-Methylaspartate (NMDA)IBA
09/2004
1N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
09/2004
1Biomarkers (Surrogate Marker)IBA
09/2004
1EnzymesIBA
09/2004
1IonophoresIBA
05/2004
1Coloring Agents (Dyes)IBA
03/2003
1Trifluoperazine (Stelazine)FDA LinkGeneric
03/2003

Therapy/Procedure

4Microspheres (Microsphere)
10/2006 - 09/2004
1Therapeutics
04/2014